Hypogonadism in men with type 2 diabetes: practical recommendations for diagnosis, treatment, and monitoring
Functional hypogonadism is a common complication of type 2 diabetes, particularly in patients with coexisting obesity or cardiometabolic complications. Nevertheless, this disorder often remains undiagnosed. This position statement provides practical recommendations for the diagnosis, treatment, and monitoring of hypogonadism in men with type 2 diabetes. In patients with type 2 diabetes who have symptoms suggestive of androgen deficiency, measurement of serum total testosterone is recommended. The diagnosis of hypogonadism requires the coexistence of clinical symptoms and a low testosterone concentration [total testosterone < 12 nmol/L (350 ng/dL) and/or calculated free testosterone (cfT) < 220 pmol/L (65 pg/mL)], confirmed by two measurements performed at least 4 weeks apart. The diagnosis of functional hypogonadism also requires exclusion of organic causes. Management should be based on a balanced diet, regular physical activity, pharmacotherapy aimed at achieving metabolic control of diabetes, and treatment of obesity. Testosterone therapy may be considered in symptomatic men who meet the biochemical criteria, primarily to improve quality of life, sexual function, body composition, and metabolic parameters. However, it should be regarded as adjunctive treatment supporting sustainable lifestyle change. Testosterone therapy may be initiated after contraindications, including current reproductive plans, have been excluded; regular monitoring is required. A targeted medical history, appropriate diagnosis of hypogonadism, lifestyle modification, careful selection of candidates for testosterone therapy, and adequate treatment monitoring may substantially improve care for men with type 2 diabetes and hypogonadism.
Authors
- Beata Kos‐Kudła (ORCID: https://orcid.org/0000-0003-3755-1722)
- Marek A. Ruchała (ORCID: https://orcid.org/0000-0001-9743-2405)
- Alicja Hubalewska‐Dydejczyk (ORCID: https://orcid.org/0000-0001-5208-4689)
- Nadia Sawicka‐Gutaj (ORCID: https://orcid.org/0000-0003-1510-4702)
- Dorota Zozulińska‐Ziółkiewicz (ORCID: https://orcid.org/0000-0003-2995-9971)
- Jolanta Słowikowska‐Hilczer (ORCID: https://orcid.org/0000-0003-3105-1786)
- Michał Rabijewski (ORCID: https://orcid.org/0000-0002-2049-7427)
- Alicja Stańska (ORCID: https://orcid.org/0009-0008-8357-2501)
- Irina Kowalska (ORCID: https://orcid.org/0000-0001-9281-1959)
- Wojciech Zgliczyński (ORCID: https://orcid.org/0000-0002-7283-4755)
Institutions
- Poznan University of Medical Sciences (PL)
- Jagiellonian University (PL)
- Medical University of Białystok (PL)
- Medical University of Silesia (PL)
- Medical University of Lodz (PL)
Publication Details
- Journal
- Endokrynologia Polska
- Published
- 2026-11-19
- DOI
- https://doi.org/10.5603/ep.113985
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00